Výsledky vyhledávání - "Klein Robert W"

Akademický článek

Estimated economic benefits from low-frequency administration of atypical antipsychotics in treatment of schizophrenia: a decision model

Autor: Furiak Nicolas M, Gahn James C, Klein Robert W, Camper Stephen B, Summers Kent H

Publikováno v: Annals of General Psychiatry, Vol 11, Iss 1, p 29 (2012)

Abstract The objective of this study was to quantify the direct medical resources used and the corresponding burden of disease in the treatment of patients with schizophrenia. Because low-frequency administration (LFA) of risperidone guarantees adher

Externí odkaz: https://doaj.org/article/2873aec3579045a7952b6bc66649fe27

Zobrazit plný text záznamu

Akademický článek

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

Autor: Murphy Daniel R, Smolen Lee J, Klein Timothy M, Klein Robert W

Publikováno v: BMC Musculoskeletal Disorders, Vol 13, Iss 1, p 213 (2012)

Abstract Background This paper presents the model and results to evaluate the use of teriparatide as a first-line treatment of severe postmenopausal osteoporosis (PMO) and Glucocorticoid-induced osteoporosis (GIOP). The study’s objective was to det

Externí odkaz: https://doaj.org/article/0caf78e93c0c48a6a236f45c5b058fe7

Zobrazit plný text záznamu

Akademický článek

Modeling screening, prevention, and delaying of Alzheimer's disease: an early-stage decision analytic model

Autor: Siemers Eric R, Kahle-Wrobleski Kristin, Klein Robert W, Furiak Nicolas M, Sarpong Eric, Klein Timothy M

Publikováno v: BMC Medical Informatics and Decision Making, Vol 10, Iss 1, p 24 (2010)

Abstract Background Alzheimer's Disease (AD) affects a growing proportion of the population each year. Novel therapies on the horizon may slow the progress of AD symptoms and avoid cases altogether. Initiating treatment for the underlying pathology o

Externí odkaz: https://doaj.org/article/0b301a4e2213496b8202879867ad87a3

Zobrazit plný text záznamu

Akademický článek

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Autor: Smolen Lee J, Klein Robert W, Ascher-Svanum Haya, Furiak Nicolas M, Lawson Anthony H, Conley Robert R, Culler Steven D

Publikováno v: Cost Effectiveness and Resource Allocation, Vol 7, Iss 1, p 4 (2009)

Abstract Background Schizophrenia is often a persistent and costly illness that requires continued treatment with antipsychotics. Differences among antipsychotics on efficacy, safety, tolerability, adherence, and cost have cost-effectiveness implicat

Externí odkaz: https://doaj.org/article/62e5e786a1ef469e84edc05586ee0fb2

Zobrazit plný text záznamu